Table of Contents Table of Contents
Previous Page  80 / 812 Next Page
Information
Show Menu
Previous Page 80 / 812 Next Page
Page Background

S76

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

B-II related admissions have increased from $52.24 million/year to

$1.6 billion/year.

Conclusions

While mortality has slightly increased from 1998 to

2011, the cost has significantly increased from $52.24 million/year

to $1.6 billion/year, which leads to an estimated $1.55 billion/year

additional burden to US health care system. In the era of cost

conscious care, preventing B-II related hospitalization could save

billions of dollars every year. Focused efforts are needed to establish

preventive measures for B-II related hospitalization.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.014

FC11

Analysis of genetic polymorphisms,

adverse drug reactions and targeted

treatment

E. Stella

1 ,

, M. La Montagna

1

, D. Seripa

2

, M. Giuseppe

2

,

L. di Mauro

2

, A. Greco

2

, A. Rinaldi

1

, M.S. Martone

1

, A. Bellomo

1

,

M. Lozupone

1 , 3

1

University of Foggia, Department of Mental Health, Psychiatric Unit,

Asl Fg, Foggia, Italy

2

IRCCS Casa Sollievo della Sofferenza, Geriatric Unit and

Gerontology, Geriatrics Research Laboratory, Department of Medical

Sciences, San Giovanni Rotondo, Italy

3

University of Bari “A. Moro”, Department of Basic Medical Sciences,

Neurosciences and Sense Organs, Bari, Italy

Corresponding author.

Introduction

Bipolar disorders (BD) are chronic and recur-

rent psychopathological conditions characterized by therapeutic

failures (TFs), regardless of the initial choice of psychiatric med-

ication with a high prevalence of adverse drug reactions (ADRs).

Cytochrome P450(CYP)2D6 genetics has been recently suggested

to have a role in the response to treatment and extra-pyramidal

symptoms (EPS) across several psychiatric conditions.

Objectives

To evaluate interindividual differences in CYP2D6

enzyme activities, TFs and ADRs rates in BDs patients.

Aims

To tailor psychiatric medication choice and dose based on

pharmacogenetic test.

Methods

We analyzed 16 clinical relevant polymorphisms

CYP2D6 genotype in Psychiatric Unit of Foggia using the Infini-

tiTMAnalyzer; the Simpson Angus Scale (SAS) was used tomeasure

drug-induced EPS and Brief Psychiatric Rating Scale-24 (BPRS-24)

response to treatment.

Results

Ten drug-resistant patients were consecutively enrolled,

and six of these experience major ADR during therapy with wors-

ening of symptoms before screening for CYP polymorphism: BM

(*2A/*5 genotype, BPRS-24 T

0

: 63, T

14

: 51), SR (*2A/*4, BPRS-24

T

0

: 66, T

14

: 59), LT (*4/*17 BPRS-24 T

0

: 72, T

14

: 64), DC (*2A/*4A

BPRS-24 T

0

: 69, T

14

: 54), AL (*2A/*2A, BPRS-24 T

0

: 72, T

14

: 64), PA

(*2A/*2A BPRS-24 T

0

: 52, T

14

: 46).

Conclusions

According to the specific CYP2D6 polymorphism, we

personalized patients’ treatment considering that poor and exten-

sive metabolizers have different rates of ADR and responses to

treatment. CYP2D6 genotype’s knowledge is useful for the reduc-

tion of therapeutic attempt during patient clinical history, thus

reducing admission time and costs, and to guide clinicians toward

a better patient management.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.015

FC12

Trends of hospitalization for major

bipolar unspecified in USA:

A nationwide analysis

A. Sutaria

1 ,

, Z. Mansuri

1

, M. Rathod

1

, S. Shambhu

1

,

U. Mansuri

2

1

Drexel University, School of Public Health, Philadelphia, USA

2

Icahn School of Medicine at Mount Sinai, School of Public Health,

New York, USA

Corresponding author.

Objectives

Bipolar unspecified (BP-U) is an important cause of

morbidity and mortality in hospitalized patients. While BP-U has

been extensively studied in the past, the contemporary data for

impact of BP-U on cost of hospitalization are largely lacking.

Methods

We queried the Healthcare Cost and Utilization

Project’s Nationwide Inpatient Sample (HCUP-NIS) dataset

between 1998–2011 using the ICD-9 codes. Severity of comorbid

conditions was defined by Deyo modification of Charlson comor-

bidity index. Primary outcome was in-hospital mortality and

secondary outcome was total charges for hospitalization. Using

SAS 9.2, Chi

2

test,

t

-test and Cochran-Armitage test were used to

test significance.

Results

A total of 711,147 patients were analyzed; 61.33% were

female and 38.67% were male (

P

< 0.0001); 77.63% were white,

13.17% black and 9.2% of other race (

P

< 0.0001). Rate of hos-

pitalization increased from 2,310.28/million to 74,908.88/million

from 1998–2011. Overall mortality was 0.81% and mean cost of

hospitalization was $25,152.02. The in-hospital mortality reduced

from 1.24% to 0.97% (

P

< 0.0001) and mean cost of hospitalization

increased from 11,308.05$ to 32,211.67$. Total yearly spending on

BP-U related admissions have increased from $207 million/year to

$19.15 billion/year.

Conclusions

While mortality has slightly decreased from 1998 to

2011, the cost has significantly increased from $0.21 billion/year

$19.15 billion/year, which leads to an estimated $18.94 billion/year

additional burden to US health care system. In the era of cost

conscious care, preventing BP-U related hospitalization could save

billions of dollars every year. Focused efforts are needed to establish

preventive measures for BP-U related hospitalization.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.016

FC13

Trends of hospitalization for major

bipolar I (most recent episode-manic)

in USA: A nationwide analysis

A. Sutaria

1 ,

, Z. Mansuri

1

, M. Rathod

1

, S. Shambhu

1

,

U. Mansuri

2

1

Drexel University, School of Public Health, Philadelphia, USA

2

Icahn School of Medicine at Mount Sinai, School of Public Health,

New York, USA

Corresponding author.

Objectives

Bipolar I most recent episode-manic (BP-I-M) is

an important cause of morbidity and mortality in hospitalized

patients. While BP-I-Mhas been extensively studied in the past, the

contemporary data for impact of BP-I-M on cost of hospitalization

are largely lacking.

Methods

We queried the Healthcare Cost and Utilization

Project’s Nationwide Inpatient Sample (HCUP-NIS) dataset

between 1998–2011 using the ICD-9 codes. Severity of comorbid

conditions was defined by Deyo modification of Charlson comor-

bidity index. Primary outcome was in-hospital mortality and

secondary outcome was total charges for hospitalization. Using

SAS 9.2, Chi

2

test,

t

-test and Cochran-Armitage test were used to

test significance.